BC
Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
$22.64 -0.53% (-$0.12)
1M -3.99%
Market Cap $1.48B
P/E Ratio -
Div. Yield -
ROE 41.49%
Piotroski F-Score Weak
1/9Valuation
64 /100
Fair P/B 3.17x
P/E N/A
EV/FFO N/A
Growth
-
N/A EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 43.01%
Asset turnover 0.00x
ROE 41.49%
Debt
100 /100
Low Debt/Equity 0.00x
Current ratio 11.59x
Int. coverage N/A
Stability
39 /100
Moderate Beta -0.82x
Profitable years 0
EPS volatility 41.20%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BCAX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Claire Mazumdar Clemon
Employees
103
Headquarters
Boston
Upcoming events
09 NOV
Earnings
Upcoming earnings report